Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Vitiligo: How to Most Effectively Use Ruxolitinib Cream
Description
The presentation provides an overview on the effective use of Ruxolitinib cream for treating vitiligo, emphasizing key takeaways from a recent phase three clinical trial. It highlights that repigmentation is a gradual process, advising healthcare professionals to set realistic timelines, preferably discussing data from the one-year mark with patients to manage expectations. The speaker notes that patient responses to treatment do not significantly depend on the duration or severity of vitiligo, and important factors influencing success include the immune response and the area of the body being treated. Notably, areas with higher follicular density, like the head and neck, tend to respond better than areas without, such as the digits. Continued application of the cream is encouraged for maintaining repigmentation, as patients who consistently use the cream for longer periods tend to have better outcomes. The session also touches on potential side effects like mild acne and discusses the feasibility of using the cream off-label for larger body surface areas while noting that even once-daily application can be effective. The aim of the presentation was to prepare for an engaging Q&A session with experts, emphasizing practical advice grounded in the latest clinical data.
View moreConclusions
- Ruxolitinib cream significantly improves facial repigmentation in patients with vitiligo, with about half achieving 75% or more repigmentation after one year.
- Repigmentation typically takes longer than expected, often requiring up to two years for optimal results.
- Patient expectations must be managed to prevent disappointment due to the gradual nature of repigmentation.
- Factors such as longer duration of treatment and the patient's immune response may influence the effectiveness of Ruxolitinib cream.
- The severity and duration of vitiligo do not significantly affect treatment response, as long-term and short-term patients may respond equally well to Ruxolitinib.
- Acne is a common side effect of Ruxolitinib cream but is generally mild and treatable.
- Continuing treatment after initial repigmentation enhances the durability of the results, suggesting that patients should be encouraged to maintain therapy even after visible improvement.
- Areas of high follicular density, like the head and neck, tend to repigment faster compared to areas with fewer hair follicles.
- Patients may still see continuous improvement in repigmentation even after one year of treatment, as additional responses can occur over time.
- Rothstein B et al JAAD 2017
- Rosmarin D, et al. EADV 2023, P2246. Sponsored by Incyte Corporation